Literature DB >> 9009443

Factor V Leiden mutation investigated by amplification created restriction enzyme site (ACRES) in PNH patients with and without thrombosis.

K Nafa1, M Bessler, P Mason, T Vulliamy, P Hillmen, H Castro-Malaspina, L Luzzatto.   

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired chronic hemolytic anemia characterized by intravascular hemolysis, often associated with neutropenia and thrombocytopenia. Venous thrombosis, including the Budd-Chiari syndrome, is one of the major complications of PNH, but not all PNH patients develop thrombosis. The basis for the high risk of thrombosis in PNH is not known. Recent reports have shown that Factor V Leiden mutation is a common cause of increased tendency to develop thrombosis. Fifty-six PNH patients were tested for Factor V Leiden mutation using Amplification Created Restriction Enzyme Site methods. PNH patients do not show an increased frequency of Factor V Leiden mutations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9009443

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  5 in total

Review 1.  Management issues in paroxysmal nocturnal hemoglobinuria.

Authors:  Gabrielle Meyers; Charles J Parker
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

Review 2.  Thrombolytic therapy is effective in paroxysmal nocturnal hemoglobinuria: a series of nine patients and a review of the literature.

Authors:  David J Araten; Rosario Notaro; Howard T Thaler; Nancy Kernan; Farid Boulad; Hugo Castro-Malaspina; Trudy Small; Andromachi Scaradavou; Heather Magnan; Susan Prockop; Sara Chaffee; Jason Gonsky; Raymond Thertulien; Roberto Tarquini; Lucio Luzzatto
Journal:  Haematologica       Date:  2011-12-01       Impact factor: 9.941

3.  Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents.

Authors:  Antonio M Risitano; Bruno Rotoli
Journal:  Biologics       Date:  2008-06

4.  Treatment of a patient with classical paroxysmal nocturnal hemoglobinuria and Budd-Chiari syndrome, with complement inhibitor eculizumab: Case Report.

Authors:  E Mandala; C Lafaras; I Goulis; K Tsioni; V Georgopoulou; G Ilonidis
Journal:  Hippokratia       Date:  2013-01       Impact factor: 0.471

5.  Effects of factor v Leiden polymorphism on the pathogenesis and outcomes of preeclampsia.

Authors:  G K Ababio; K Adu-Bonsaffoh; E Abindau; G Narh; D Tetteh; F Botchway; D Morvey; J Neequaye; I K Quaye
Journal:  BMC Med Genet       Date:  2019-11-27       Impact factor: 2.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.